Damon Runyon identifies today’s most brilliant early career scientists and funds their innovative cancer research.
- Today’s Promising Areas of Cancer Research
- What is Cancer?
- A Broken Pipeline?
A Generation of Science at Risk
- ARISE Report
Early Career Scientists and High-Risk, High Reward Research - American Academy of Arts and Sciences
- Why We’re Losing the War on Cancer (And How To Win It)
Clifton Leaf - Fortune Magazine
December 11, 2009 > Biomarkers for improved pancreatic cancer diagnosis
Albert C. Koong, MD, PhD (Damon Runyon-Lilly Clinical Investigator ‘02-‘07) of Stanford University School of Medicine, Stanford, reported the use of multiple simultaneous measurements of biomarkers for more accurate and sensitive diagnosis of pancreatic cancer. The studies identified a panel of biomarkers CA19-9, OPN and CHI3L1 that improves accuracy of pancreatic cancer diagnosis compared to CA19-9 alone. Levels of two markers, CEA and CA125, can predict survival for advanced pancreatic cancer patients. These findings were published in the Journal of Translational Medicine.